Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,674 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06439966 | Expanded Access to ABBV-787 | no longer available | — | — | AbbVieINDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT00590915 | Erwinase Master Treatment Protocol(EMTP) | no longer available | — | — | Phoenix Children's HospitalOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT05161598 |
| Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) |
| no longer available |
| — |
| — |
| Janssen Research & Development, LLCINDUSTRY |
| 0 |
| Dec 16, 2025 |
| clinicaltrials |
| NCT05503550 | Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Dec 16, 2025 | clinicaltrials |
| NCT05269771 | MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 8 | Nov 5, 2025 | clinicaltrials |
| NCT05918913 | Expanded Access Program for Revumenib | no longer available | — | — | Syndax PharmaceuticalsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04452994 | Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 13, 2025 | clinicaltrials |
| NCT02158767 | Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts. | no longer available | — | — | Leland MethenyOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05238311 | Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | no longer available | — | — | PfizerINDUSTRY | 0 | Feb 4, 2025 | clinicaltrials |
| NCT05215405 | Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL | no longer available | — | — | Kathleen LudwigOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04052854 | A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies | no longer available | — | — | BeiGeneINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03420430 | Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care | no longer available | — | — | Genelux CorporationINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05462639 | Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma(MAGNETISMM17) | no longer available | — | — | PfizerINDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT05219266 | Managed Access Programs for PKC412, Midostaurin | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 28, 2024 | clinicaltrials |
| NCT03592576 | Expanded Access to Navitoclax | no longer available | — | — | AbbVieINDUSTRY | 0 | May 6, 2024 | clinicaltrials |
| NCT04757259 | Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib | no longer available | — | — | Alexion Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 19, 2024 | clinicaltrials |
| NCT02856438 | Early Patient Access Treatment Use Protocol CA204-220 | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT02368301 | Expanded Access Treatment Protocol CA204-143 | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 30, 2023 | clinicaltrials |
| NCT02822495 | Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies | no longer available | — | — | Atara BiotherapeuticsINDUSTRY | 0 | Jun 15, 2023 | clinicaltrials |
| NCT04518644 | Nilotinib, for Patients With CML-CP or CML-AP | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 28, 2023 | clinicaltrials |
| NCT05131438 | An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) | no longer available | — | — | EQRx International, Inc.INDUSTRY | 1 | Mar 27, 2023 | clinicaltrials |
| NCT05692050 | Expanded Access to Epcoritamab | no longer available | — | — | AbbVieINDUSTRY | 0 | Feb 3, 2023 | clinicaltrials |
| NCT00419367 | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2022 | clinicaltrials |
| NCT04559555 | MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 9, 2022 | clinicaltrials |
| NCT04678466 | Flotetuzumab Expanded Access Program | no longer available | — | — | MacroGenicsINDUSTRY | 0 | May 31, 2022 | clinicaltrials |
| NCT02258490 | Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | no longer available | — | — | Emory UniversityOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT03594162 | Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03914885 | Compassionate Use Re-Infusion of ATLCAR.CD30 | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03126617 | Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 29, 2021 | clinicaltrials |
| NCT04453397 | Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma | no longer available | — | — | TeneoOne Inc.INDUSTRY | 1 | Sep 23, 2021 | clinicaltrials |
| NCT01200017 | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant | no longer available | — | — | Christopher DvorakOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT01196208 | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | no longer available | — | — | Seagen Inc.INDUSTRY | 15 | Sep 21, 2020 | clinicaltrials |
| NCT02568943 | An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 6 | Apr 8, 2020 | clinicaltrials |
| NCT03723057 | Expanded Access for AG-221 | no longer available | — | — | CelgeneINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02715843 | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | no longer available | — | — | Molecular Templates, Inc.INDUSTRY | 1 | Oct 11, 2019 | clinicaltrials |
| NCT03850704 | Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | no longer available | — | — | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 22, 2019 | clinicaltrials |
| NCT03723096 | Expanded Access for CC-4047 | no longer available | — | — | CelgeneINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03409081 | Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | no longer available | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 13, 2018 | clinicaltrials |
| NCT02666209 | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | no longer available | — | — | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT00423826 | Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease | no longer available | — | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT02204553 | Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00799539 | A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients | no longer available | — | — | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00999414 | UARK 2009-32 Compassionate Use Study of Carfilzomib(2009-32) | no longer available | — | — | University of ArkansasOTHER | 1 | Oct 26, 2015 | clinicaltrials |
| NCT02541643 | Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma | no longer available | — | — | Sundar JagannathOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01549548 | Compassionate Use Ponatinib | no longer available | — | — | OHSU Knight Cancer InstituteOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00302016 | Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 34 | Aug 26, 2011 | clinicaltrials |
| NCT00413270 | Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2011 | clinicaltrials |
| NCT00517894 | Dose-Dense Therapy in Aggressive Lymphoma | no longer available | — | — | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 0 | Aug 17, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials